GRAIL (NASDAQ:GRAL) President Joshua Ofman Sells 9,692 Shares

GRAIL, Inc. (NASDAQ:GRAL) President Joshua Ofman sold 9,692 shares of the company’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $64.00, for a total value of $620,288.00. Following the transaction, the president owned 478,182 shares of the company’s stock, valued at approximately $30,603,648. The trade was a 1.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

GRAIL Price Performance

Shares of GRAL opened at $65.54 on Friday. The company has a market cap of $2.36 billion, a P/E ratio of -5.00 and a beta of 4.11. The stock has a fifty day moving average price of $38.69 and a 200 day moving average price of $37.12. GRAIL, Inc. has a 12 month low of $12.33 and a 12 month high of $73.74.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($3.18) EPS for the quarter, missing analysts’ consensus estimates of ($3.14) by ($0.04). The company had revenue of $35.54 million for the quarter, compared to the consensus estimate of $37.57 million. GRAIL had a negative return on equity of 16.64% and a negative net margin of 329.86%. As a group, research analysts anticipate that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Wall Street Analyst Weigh In

GRAL has been the subject of a number of recent research reports. UBS Group set a $75.00 price objective on GRAIL in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research note on Saturday, September 27th. Finally, Canaccord Genuity Group increased their price target on GRAIL from $43.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $56.67.

Institutional Trading of GRAIL

Several institutional investors have recently modified their holdings of GRAL. Caldwell Sutter Capital Inc. acquired a new stake in shares of GRAIL in the first quarter valued at $28,000. KBC Group NV lifted its holdings in shares of GRAIL by 187.7% in the first quarter. KBC Group NV now owns 1,430 shares of the company’s stock valued at $37,000 after buying an additional 933 shares during the period. S.A. Mason LLC lifted its holdings in shares of GRAIL by 50.1% in the first quarter. S.A. Mason LLC now owns 1,499 shares of the company’s stock valued at $38,000 after buying an additional 500 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of GRAIL by 768.1% in the second quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock valued at $42,000 after buying an additional 722 shares during the period. Finally, NewEdge Advisors LLC lifted its holdings in shares of GRAIL by 390.3% in the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock valued at $45,000 after buying an additional 1,401 shares during the period.

GRAIL Company Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.